Source:http://linkedlifedata.com/resource/pubmed/id/20463599
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2010-5-26
|
pubmed:abstractText |
We earlier showed that therapeutic vaccination of FVB/N mice with alphaviral replicon particles expressing rat neuET-VRP induced regression of established neu-expressing tumors. In this study, we evaluated the efficacy of neuET-VRPs in a tolerant mouse model using mice with transgenic expression of neu. Using the same approach that induced regression of 70 mm(2) tumors in FVB/N mice, we were unable to inhibit tumor growth in tolerant neu-N mice, despite showing neu-specific B-cell and T-cell responses post vaccination. As neu-N mice have a limited T-cell repertoire specific to neu, we hypothesized that the absence of these T cells led to differences in the vaccine response. However, transfer of neu-specific T cells from vaccinated FVB/N mice was not effective in inducing tumor regression, as these cells did not proliferate in the tumor-draining lymph node. Vaccination given with low-dose cyclophosphamide to deplete regulatory T cells delayed tumor growth but did not result in tumor regression. Finally, we showed that T cells given with vaccination were effective in inhibiting tumor growth, if administered with approaches to deplete myeloid-derived suppressor cells. Our data show that both central deletion of lymphocytes and peripheral immunosuppressive mechanisms are present in neu-N mice. However, the major impediment to successful vaccination is the peripheral tumor-induced immune suppression.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1537-4513
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
33
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
482-91
|
pubmed:meshHeading |
pubmed-meshheading:20463599-Adoptive Transfer,
pubmed-meshheading:20463599-Alphavirus,
pubmed-meshheading:20463599-Animals,
pubmed-meshheading:20463599-Autoantigens,
pubmed-meshheading:20463599-Cancer Vaccines,
pubmed-meshheading:20463599-Cell Proliferation,
pubmed-meshheading:20463599-Female,
pubmed-meshheading:20463599-Immunosuppression,
pubmed-meshheading:20463599-Mice,
pubmed-meshheading:20463599-Mice, Transgenic,
pubmed-meshheading:20463599-Myeloid Cells,
pubmed-meshheading:20463599-Rats,
pubmed-meshheading:20463599-Receptor, erbB-2,
pubmed-meshheading:20463599-Remission Induction,
pubmed-meshheading:20463599-Self Tolerance,
pubmed-meshheading:20463599-T-Lymphocytes,
pubmed-meshheading:20463599-Tumor Escape
|
pubmed:year |
2010
|
pubmed:articleTitle |
The immunosuppressive tumor environment is the major impediment to successful therapeutic vaccination in Neu transgenic mice.
|
pubmed:affiliation |
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599-7295, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|